Alumis (ALMS) Consolidated Net Income (2023 - 2026)
Alumis' (ALMS) quarterly Consolidated Net Income came in at -$142.2 million in Q2 2026, down 339.52% year-over-year from $59.4 million in Q2 2025, and down 192.34% quarter-over-quarter from -$48.6 million in Q4 2025.
Analysis
Alumis (ALMS) Consolidated Net Income (2023 - 2026) Analysis & Trends
Alumis (ALMS) has reported Consolidated Net Income for 4 consecutive years, with -$142.2 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Consolidated Net Income fell 339.52% year-over-year to -$142.2 million in Q2 2026; TTM through Jun 2026 was -$242.2 million, a 43.95% decrease from a year earlier, with the FY2025 full-year figure at -$199.0 million, up 14.39% from the prior year.
- Consolidated Net Income was -$142.2 million for Q2 2026 at Alumis, down from -$48.6 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at $59.4 million in Q2 2025 and troughed at -$142.2 million in Q2 2026.
- A 4-year average of -$57.9 million and a median of -$48.1 million in 2024 frame the typical range for Consolidated Net Income.
- Across the five-year window, Consolidated Net Income surged 205.05% in 2025 and sank 339.52% in 2026, its largest moves.
- Over 4 years, Consolidated Net Income stood at -$40.1 million in 2023, then increased by 17.85% to -$33.0 million in 2024, then slumped by 47.51% to -$48.6 million in 2025, then sank by 192.34% to -$142.2 million in 2026.
- The last three Consolidated Net Income figures came in at -$142.2 million (Q2 2026), -$48.6 million (Q4 2025), and -$110.8 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -782.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 601.00 Mn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -290.61 Mn |
| 10 | Alumis | 966.94 Mn | 464.65 Mn | - | -142.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -142.18 Mn |
| Dec 31, 2025 | -48.64 Mn |
| Sep 30, 2025 | -110.75 Mn |
| Jun 30, 2025 | 59.36 Mn |
| Mar 31, 2025 | -101.53 Mn |
| Dec 31, 2024 | -32.97 Mn |
| Sep 30, 2024 | -93.12 Mn |
| Jun 30, 2024 | -56.51 Mn |
| Mar 31, 2024 | -47.59 Mn |
| Dec 31, 2023 | -40.13 Mn |
| Sep 30, 2023 | -43.76 Mn |
| Jun 30, 2023 | -36.71 Mn |